1. Home
  2. CWD vs REVB Comparison

CWD vs REVB Comparison

Compare CWD & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CaliberCos Inc.

CWD

CaliberCos Inc.

HOLD

Current Price

$1.82

Market Cap

4.5M

Sector

Finance

ML Signal

HOLD

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$1.04

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CWD
REVB
Founded
2009
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5M
5.1M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
CWD
REVB
Price
$1.82
$1.04
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
143.7K
112.1K
Earning Date
11-13-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$24,657,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$26.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.63
$0.83
52 Week High
$48.00
$60.48

Technical Indicators

Market Signals
Indicator
CWD
REVB
Relative Strength Index (RSI) 28.53 51.23
Support Level $1.96 $0.90
Resistance Level $2.35 $1.00
Average True Range (ATR) 0.21 0.07
MACD 0.02 0.04
Stochastic Oscillator 3.82 78.84

Price Performance

Historical Comparison
CWD
REVB

About CWD CaliberCos Inc.

CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Share on Social Networks: